Anixa Biosciences
75 articles with Anixa Biosciences
-
Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology
12/1/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that it has entered into a license agreement with Clev
-
Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine
11/23/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its prophylactic breast cancer vaccine has been filed with the U.S. Food and Drug Administration.
-
Anixa Biosciences to Host Conference Call to Provide Update on Programs
10/27/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern.
-
Anixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference
9/8/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual 2020 H.C. Wainwright Global Investment Conference being held September 14-16 , 2020.
-
Anixa and OntoChem Announce Identification of Additional Covid-19 Compounds
8/13/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have identified additional candidates through their in silico screening study. In addition to four compounds that target an endoribonuclease (als
-
Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission
7/28/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its prophylactic breast cancer vaccine is making progress towards clinical trials.
-
Anixa Biosciences Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
7/20/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its stockholders, employees and others,
-
Anixa Biosciences' CAR-T Cancer Therapy Receives Intention to Grant Notice from the European Patent Office
7/10/2020
Anixa Biosciences, Inc. announced that the European Patent Office has issued an Intention to Grant notice for the first European patent covering Anixa's novel CAR-T cancer treatment technology, which has been licensed from The Wistar Institute and is being developed at the Moffitt Cancer Center.
-
Anixa and OntoChem Announce Completion of Initial Screening Program and Identification of Additional Covid-19 Compounds
7/6/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have completed the initial in silico screening process of their drug discovery program and have identified an additional specific compound, as well
-
Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline
7/2/2020
Focusing Resources on Existing Breast Cancer Vaccine, CAR-T Therapy and Covid-19 discovery Technologies and Expanding Therapeutics Portfolio
-
Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays
6/1/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and Ont
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
-
Anixa Biosciences and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate
5/4/2020
Anixa Biosciences, Inc., a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, announced that it, with partner OntoChem GmbH, has identified its first therapeutic candidate against Covid-19, and has advanced the compound into biological testing.
-
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid Biopsy Technology
4/23/2020
Anixa Biosciences, Inc., a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, announced the publication of a peer-reviewed journal article in Biomarker Insights.
-
Anixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics
4/20/2020
Anixa to Host a Conference Call Tuesday, April 21, 2020, 4:15 p.m. ET to Discuss COVID-19 Project.
-
Anixa Biosciences Announces Presentation at AI and Big Data in Cancer Conference
3/2/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data related to Anixa's recently launched Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC) will be presented at the "AI and Big Data in Cancer: From Innovation to Impact" conference
-
Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program
2/12/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that the research team lead by Dr. Jose Conejo-Garcia, Chair of the Department of Immunology at Moffitt Cancer Center, Anixa's development partner, has completed and validated the reformulation of the viral vector necessary for its CAR-T program
-
Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference
1/6/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data from studies utilizing Cchek™, the company's artificial intelligence (AI) driven cancer detection technology, will be presented at the American Association for Cancer Research (AACR) Special Conference
-
Anixa Biosciences to Present at Biotech Showcase 2020
12/23/2019
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that its chief executive officer, Dr. Amit Kumar, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.
-
Anixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test
12/16/2019
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the commercial launch of its Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC), the first test developed with the Cchek™ artificial intelligence driven, flow cytometry based, liquid biopsy technology platform.